Gina Mazzariello - 12 Aug 2025 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Legal Officer
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Issuer symbol
AMLX
Transactions as of
12 Aug 2025
Net transactions value
-$246,148
Form type
4
Filing time
14 Aug 2025, 16:20:11 UTC
Previous filing
27 May 2025
Next filing
02 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mazzariello Gina Chief Legal Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE /s/ Joshua B. Cohen, as Attorney in Fact 14 Aug 2025 0001913765

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Sale $121,102 -15,000 -8% $8.07 171,969 12 Aug 2025 Direct F1, F2
transaction AMLX Common Stock Sale $125,046 -15,000 -8.7% $8.34 156,969 13 Aug 2025 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2025.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.82 to $8.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.13 to $8.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.